Glucocorticoid

BOSTON — Crinecerfont lowered androstenedione levels and allowed for lower glucocorticoid doses for children with classic congenital adrenal hyperplasia, according to findings from the CAHtalyst Pediatric phase 3 trial.

BOSTON — Adults with congenital adrenal hyperplasia receiving an oral nonsteroidal treatment saw a marked reduction in daily glucocorticoid dose at 24 weeks with maintenance of androgen control compared with placebo, researchers reported.

Glucocorticoid tapering, education and treatment of adrenal crisis are three of the main focuses of a new clinical practice guideline on glucocorticoid-induced adrenal insufficiency.

In this video, Sebastian E. Sattui, MD, MS, discusses complications that can arise in patients with polymyalgia rheumatica.

In this video, Sebastian E. Sattui, MD, MS, discusses currently available and emerging treatment options in polymyalgia rheumatica.

In this video, Sebastian E. Sattui, MD, MS, discusses challenges in making a polymyalgia rheumatica diagnosis.

Among patients with polymyalgia rheumatica who relapse during glucocorticoid tapering, sarilumab is effective at enabling them achieve sustained remission and lowering cumulative glucocorticoid use, according to data.

SAN DIEGO — Maintaining immunosuppression with or without low-dose glucocorticoids is superior to withdrawing both therapies in preventing relapses in IgG4-related disease, according to data presented at ACR Convergence 2023.

The FDA granted breakthrough therapy designation for an oral non-glucocorticoid medication for the treatment of congenital adrenal hyperplasia, according to an industry press release.

SAN DIEGO — Glucocorticoid doses as small as 5 mg per day, in durations as short as 30 days, and a use period as long as 1 year all increase the risk for major adverse cardiac events in rheumatoid arthritis, said a speaker here.